Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZ-PEARL: Pitavastatin +/- Ezetimibe vs Atorvastatin on Glucose Metabolism in ASCVD with Metabolic Syndrome
NCT05705804Recruiting
- Sponsor
- Yonsei University
- Start
- Jun 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pitavastatin in dyslipidemia, atherosclerotic cardiovascular disease (ASCVD) and metabolic syndrome (3 arms), sponsored by Yonsei University. Primary endpoint: Homeostatic Model Assessment for Insulin Resistance at 24 weeks. Started Jun 2023; status: recruiting.
02
Drugs
pitavastatin
03
Conditions
dyslipidemiaatherosclerotic cardiovascular disease (ASCVD)metabolic syndrome
Beyond the preview
Go deeper on NCT05705804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705804.